FPM conversations are designed to give members the unique opportunity to engage with eminent figures in industry, government, regulation, academia and clinical practice. The evenings consist of a buffet dinner, followed by around 1½ hours of discussion and debate, with drinks and networking to finish – a perfect combination of the professional and the social.
If you have any thoughts or ideas on who could lead conversations and on what topics then please get in touch with us (firstname.lastname@example.org).
Pharmaceutical Medicine Liability – “Do I Need a Get Out of Jail Free Card”?
Date – Thursday 17 September 2020 Platform – Webinar hosted on Zoom
Continuing the popular FPM Conversation Series, this videoconference meeting discussed and debated some of the common pitfalls and legal liabilities (civil and criminal) potentially facing physician/scientist professionals working in Pharmaceutical Medicine and how attendees could avoid them!
Bringing together an expert panel with extensive hands-on experience in pharmaceutical medicine personal and professional legal risk minimisation, this FPM Conversation explored questions such as:
Is there anything I should be especially concerned about legally regarding products developed or marketed to treat COVID-19?
Have I been writing emails/slides “appropriately”?
Am I at legal risk as a supervisor/manager?
Does the UK QP have new liabilities post-Brexit?
Oh Gosh – I’ve been deposed! – what does this mean for me?
Event chair Dr Craig Hartford
Biotechs/Startups – a Pharmaceutical Medicine Perspective
Date – Wednesday 8 July 2020 Platform – Webinar hosted on Zoom
Moving the popular FPM Conversation Series into the virtual environment, this well-attended videoconference meeting debated the issues and opportunities, and looked at practical solutions, surrounding the challenges of working in a Biotech/Start-Up.
Bringing together a panel of medical and non-medical leaders from start-up/biotech companies and venture capital organisations, the conversation encompassed the following topics:
What are the main differences between working in big pharma and a start-up/biotech?
How can you overcome challenges of working in a small company?
How does a start-up/biotech convince investors to invest?
What are some of the regulatory, scientific, legal, compliance and logistical challenges?
How can you best handle acquisitions?
How should you support and get the most out of academics?
Dr Emma Harvey FFPM Global Head of Medical Affairs at F2G Ltd
Dr Shahzad Malik
Founding General Partner at Advent Life Sciences
Dr Duncan McHale
Clinical geneticist and early drug development expert
Dr Eliot Foster
Chief Executive Officer at F-star Therapeutics Ltd
Event chair Dr Craig Hartford Independent pharmaceutical physician and committee member of the FPM Policy and Communications Group
The Commercial and Medical Partnership
A Marriage Made in Heaven, or Fraternising with the Enemy?
The role of Medical Affairs has evolved considerably in the last two decades, but one thing has not changed: Medical and Commercial often fail to engage fully and Medical Affairs can play a “husband/wife of…” role rather than being an equal partner in this “marriage”.
A recent survey of Senior Medical and Commercial leaders shows that a lack of mutual trust, failure to understand each others’ roles, inability to work as complementary partners and lack of good communication underpin the key challenges in this relationship.
And yet there may be a better way – just as in any marriage getting the basics right can help; there is an opportunity to step up the Medical contribution from one of “Support Function” to a true “Strategic Partner”.
Bringing together a panel of senior Commercial and Medical Leaders this FPM conversation covered the following topics:
Developing shared strategy with commercial partners
Executing against the strategy
Execution and measuring added value
The leadership mind-set and language necessary to be a strategic partner.
Dr Bobby Mulrooney
General Manager UK & Ireland, Portola Pharmaceuticals
Dr Rav Seeruthun
Medical Director, Roche UK
Trust and transparency in the pharmaceutical industry: How far have we come?
It is 2019 and the pharmaceutical industry still struggles to be trusted. Reports of falsifying data, bribery and corruption, price hikes and manipulative patent litigation have steadily soured the public’s view of the pharmaceutical industry. Yet, the drugs that pharmaceutical companies produce save millions of lives a year and improve the lives of millions more. So, what is going wrong?
Pharmaceutical companies have made only modest progress in improving trust over the last few years. The Edelman ‘Trust Barometer’ shows that, globally, public trust in the industry has edged up marginally from 55% in 2015 to 57% in 2019. In the UK the figure is 50% in 2019. Why is it not higher for an industry whose business is saving lives?
• How can the industry restore its credibility in the eyes of patients, policymakers and the rest of the taxpaying public?
• Are prices too high? What can we do about it?
• Is moving from clinical medicine to a job in industry still thought of as moving to the ‘dark side’? Why?
• ‘Patient-centricity’ and ‘patient engagement’ How can it make a real difference? Can familiarity breed trust?
• Do companies adequately and accurately warn patients and clinicians about the risks as well as the benefits of taking medicines?
These are key questions that the pharmaceutical industry continues to grapple with, as trust and transparency holds more weight among the public than ever before. We, as doctors working in all aspects of the industry – companies, regulators, academia – must do more, in the interests of patients and wider society. We must strive for greater engagement and understanding, and further development of appropriate regulations and guidelines.
In this FPM ‘conversation’ event we brought together a panel of leaders in this field to discuss issues around public trust and transparency:
Mike Thompson, Chief Executive, ABPI Alastair Benbow, Chief Development and Medical Officer, Norgine Fiona Fox, CEO, Science Media Centre